Tradestie Institutional Equity Comparison Engine · Market Close Feb 11, 2026

AVDL vs FGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–2 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 3 – 1 FGEN (2 Tie) Matrix Metrics: AVDL 8 – 2 FGEN

As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over FibroGen, Inc (FGEN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas FGEN carries 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FGEN 61.2/100 BUY) and 0.14β · 2% Vol risk profile, whereas FGEN leads top-line expansion (+774.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs FGEN
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
FGEN NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
TTM Revenue $8.3M
Forward P/E 61.4x
Beta / 30D Vol -20.79β · 102% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.2 · SMA20: $8.88 · SMA50: $9.26

6-Pillar Scorecard Institutional Category Breakdown (AVDL 3 – 1 FGEN)

Columns: Metric · AVDL · FGEN
1. Valuation Multiples AVDL
Forward P/E 28.8x 61.4x
Trailing P/E 16.8x 61.4x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 4.4x
2. Growth & Scale FGEN
Revenue Growth (YoY) +54.9% +774.8%
Earnings Growth (YoY) +0.0% +53.6%
TTM Revenue (USD) $249M $8.3M
Market Cap $2.1B $36.5M
3. Profitability & Quality AVDL
Gross Margin 94.9% N/A
Operating Margin 2.5% -499.1%
Net Profit Margin -0.1% 2598.9%
Return on Equity (ROE) -0.3% -1015.8%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) $2.7M EBITDA -$58M EBITDA
Cash Flow Margin 1.1% EBITDA Mgn N/A
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE -1015.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 2.4% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (8) vs FGEN (2)
Institutional Metric AVDL FGEN Criterion Row Edge
Market Capitalization
Scale
$2.1B $36.5M Larger Scale AVDL
Trailing P/E Ratio
Valuation
16.8x 61.4x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x 61.4x Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% +774.8% Higher Growth FGEN
Operating Margin (TTM)
Profitability
2.5% -499.1% Higher Margin AVDL
Net Profit Margin
Profitability
-0.1% 2598.9% Higher Margin FGEN
Return on Equity (ROE)
Capital Efficiency
-0.3% -1015.8% Higher ROE AVDL
52-Week Range Position
Momentum
89% ($6–$24) 44% ($0–$22) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol -20.79β · 102% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 61.2 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $8.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 4.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) -$58M EBITDA (-1015.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FGEN +15.84 pp
AVDL: +0.73% · FGEN: +16.57%
3M Horizon AVDL +60.87 pp
AVDL: +48.58% · FGEN: -12.29%
6M Horizon AVDL +68.26 pp
AVDL: +125.13% · FGEN: +56.87%
1Y Horizon AVDL +158.57 pp
AVDL: +136.52% · FGEN: -22.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs FGEN. Trailing 12-month operating profitability (AVDL 2.5% vs FGEN -499.1%) and valuation multiples (AVDL 28.8x vs FGEN 61.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
FGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross MarginN/A
Op. Margin-499.1%
ROE / Fwd P/E-1015.8% · 61.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs FGEN Key Questions & Quantitative Answers

As of Feb 11, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over FibroGen, Inc (FGEN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas FGEN carries 61.2/100 (BUY) at $9.71 (61.4x Forward P/E, -499.1% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. FGEN 61.2/100 BUY) and 0.14β · 2% Vol risk profile, whereas FGEN leads top-line expansion (+774.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

FGEN leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with FGEN at +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $8.3M for FGEN. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FGEN.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus FGEN (-1015.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 11, 2026. For educational research only; not investment advice.